Panacea Biotec files suit seeking to restrain Sanofi from marketing fully liquid hexavalent vaccine

18 May 2021 Evaluate

Panacea Biotec has filed a suit before the Delhi High Court seeking to restrain Sanofi Healthcare India from marketing a fully liquid hexavalent vaccine. A case has been filed in order to stop infringement of its patent for fully liquid whole cell pertussis based fully liquid Hexavalent vaccine EasySix.

Panacea Biotec is a leading research based Biotechnology Company with established research, manufacturing and marketing capabilities.

Panacea Biotec Share Price

563.65 26.60 (4.95%)
29-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.80
Dr. Reddys Lab 1176.25
Cipla 1541.00
Lupin 2067.40
Zydus Lifesciences 887.95
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...